Increased oxidative stress in epileptic children treated with valproic acid

Related Experiment Video

Updated: Jul 8, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Alberto Verrotti1, Alessandra Scardapane, Emilio Franzoni

  • 1Department of Medicine, Section of Pediatrics, University of Chieti, Italy. averrott@unich.it

Epilepsy Research
|January 1, 2008
PubMed

Insights

Valproic Acid (VPA) treatment in epileptic children can lead to oxidative stress, particularly in those who become overweight. This highlights the importance of monitoring metabolic and oxidative status during VPA therapy.

Area of Science:

  • Pediatric Neurology
  • Metabolic Disorders
  • Oxidative Stress Research

Background:

  • Epilepsy affects children, and treatments like Valproic Acid (VPA) are common.
  • Obesity is a growing concern in pediatric populations.
  • Oxidative stress plays a role in various chronic conditions.

Purpose of the Study:

  • To investigate the impact of VPA treatment on oxidative status in epileptic children.
  • To compare oxidative markers in non-obese versus overweight children receiving VPA.
  • To assess changes in metabolic parameters alongside oxidative status.

Main Methods:

  • Prospective study of 31 epileptic children undergoing 1 year of VPA therapy.
  • Comparison with 31 age-, sex-, and BMI-matched healthy controls.
  • Measurement of serum insulin, glucose, plasma Vitamin E, Lag phase, and Malondialdehyde (MDA) levels.

Main Results:

  • 11 (35.5%) epileptic patients developed obesity during VPA treatment.
  • Obese VPA-treated patients showed significantly lower Vitamin E and higher MDA and Lag phase levels.
  • These oxidative markers were compared between obese VPA-treated, non-obese VPA-treated, and control groups.

Conclusions:

  • Oxidative stress emerges in overweight epileptic children after 1 year of VPA therapy.
  • Obesity appears to be a key factor driving increased oxidant markers.
  • Elevated oxidative stress may predispose to future endothelial dysfunction and atherosclerosis.
Abstract

More Related Videos

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...